Advanced Filters
noise

Songpa-gu, Korea, Republic of Clinical Trials

A listing of Songpa-gu, Korea, Republic of clinical trials actively recruiting patients volunteers.

Found 1,179 clinical trials
H Hye Bin Kim, MD, PhD

Impact of CES1 Genotype on Remimazolam

Remimazolam is primarily metabolized via CES1, and other drugs that are commonly metabolized by CES1 are known to have their pharmacokinetics and clinical effects affected by genetic polymorphisms in CES1. The goal of this observational study is to investigate the impact of the CES1 genotype on the pharmacokinetics, safety, and …

19 - 64 years of age All Phase N/A
H Hyun-Kyu Yoon, MD

Effect of Cuff Pressure of Endotracheal Tube on POST

The main objective of this study is to evaluate the association between the duration of intraoperative cuff overpressure and the development of postoperative sore throat.

19 years of age All Phase N/A

Milrinone on Right Ventricular Strain in Cardiac Surgery

The purpose of this study is to analyze the changes in right ventricular strain before and after milrinone administration in order to find out whether milrinone improves RV systolic performance in patients undergoing cardiac surgery.

20 years of age All Phase N/A
S Sehhoon Park

Developing Artificial Intelligence-based Algorism to Predict Side Effects and Symptoms From Chemotherapy

In this study, the investigators obtain wearable disease based biomarkers from patients diagnosed with cancer and undergoing chemotherapy, and simultaneously measure patient self-reported adverse events through an app to evaluate chemotherapy completion rates, emergency room visits, and frequency of CTCAE adverse events. The investigators will develop an artificial intelligence-based algorism …

20 years of age All Phase N/A
C ChangSik Park, MD. Ph D

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial

This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months

19 - 75 years of age All Phase N/A
J Joo Kyung Park, MD

Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid

The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through …

18 years of age All Phase N/A
C Chang Wook Jeong, M.D., Ph.D.

Seoul National University Prospectively Enrolled Registry for Prostate Cancer With Active Surveillance

In this study, the investigators aim to establish the prostate cancer active surveillance prospective cohort in our institution, and finally investigate the 5 year rates of reclassification during active surveillance as the primary endpoint of the current study.

40 - 80 years of age Male Phase N/A
H Hyung-Jun Kim, MD

Rehabilitation Exercise and Education of Airway Clearance Technique in NTM-PD: A Prospective Cohort Study

The goal of this observational study is to evaluate the effects of pulmonary rehabilitation and airway clearance education in adults with nontuberculous mycobacterial pulmonary disease (NTM-PD). The main questions it aims to answer are: Does pulmonary rehabilitation and airway clearance training improve lung function, symptom relief, and quality of life …

20 years of age All Phase N/A
J Jun-Hyung Cho, M.D.

Tegoprazan and Amoxicillin Dual Therapy

Dual therapy for Helicobacter pylori refers to a treatment regimen that combines two agents: a potent acid suppressor (such as a proton pump inhibitor [PPI] or a potassium-competitive acid blocker [PCAB]) and the antibiotic amoxicillin. This approach is increasingly recognized as a viable alternative to traditional triple or quadruple therapies, …

20 - 80 years of age All Phase N/A
J Jun-Hyung Cho, M.D.

Tegoprazan- Versus PPI-based H. Pylori Eradication

In 2015, vonoprazan, a potassium-competitive blocker (P-CAB), was launched in Japan and used as an alternative for proton pump inhibitors (PPIs) for eradicating Helicobacter pylori. In recent studies, vonoprazan-based triple therapy significantly increased the eradication rate from 72.8% to 87.9%, compared to PPI treatment group. Accordingly, the Japanese Helicobacter treatment …

20 - 80 years of age All Phase N/A

Simplify language using AI